FDA Approves First Drug to Prevent Pancreatitis Attacks

Millions of Americans with severely high triglycerides just got a breakthrough that could save their lives.

The FDA approved TRYNGOLZA this week as the first and only treatment to reduce the risk of acute pancreatitis in adults with severe hypertriglyceridemia. This condition affects people whose triglyceride levels soar above 500 mg/dL, putting them at constant risk of sudden, debilitating pancreas attacks.

For patients living with this condition, the fear is real and relentless. Acute pancreatitis strikes without warning, causing excruciating abdominal pain that often leads to repeated hospitalizations, permanent organ damage, and can even be fatal. Until now, doctors had limited tools to help.

Dr. Archna Bajaj, who treats these patients at the University of Pennsylvania, called the approval transformational. "I have seen firsthand how challenging it can be for patients with severe hypertriglyceridemia to lower their triglycerides below 500 mg/dL, despite background therapies and lifestyle changes," she said.

The results from clinical trials published in The New England Journal of Medicine speak for themselves. TRYNGOLZA lowered triglyceride levels by up to 72% at six months and sustained those reductions for a full year. Even more impressive, it cut pancreatitis attacks by up to 91%.

Among patients who completed 12 months of treatment, 86% achieved triglyceride levels below the critical 500 mg/dL threshold. The self-administered monthly injection worked so well that in high-risk patients with a history of pancreatitis, treating just four people for one year prevented one acute attack.

The Ripple Effect

This breakthrough extends far beyond individual patients. Family members who've watched loved ones suffer through repeated hospitalizations can finally breathe easier. Emergency rooms will see fewer critical cases. Healthcare systems will spend less on expensive, extended hospital stays for pancreatitis complications.

Emily Draud from the National Pancreas Foundation captured what this means for the community: "People living with severe hypertriglyceridemia often face a constant and real fear that a debilitating acute pancreatitis attack could strike at any time without warning." That fear just got dramatically smaller.

The medication demonstrated a favorable safety profile across clinical trials, with the most common side effects being injection site reactions and manageable liver enzyme increases. Ionis Pharmaceuticals, the company behind TRYNGOLZA, will make the treatment available in July with full support services to help patients access and use their medication.

After years of limited options, patients finally have a powerful tool to take control of their condition and protect themselves from one of its most dangerous complications.